Tag: alirocumab
Alirocumab receives EC approval in established atherosclerotic cardiovascular disease
The European Commission (EC) has approved the use of alirocumab (Praluent, Sanofi), a PCSK9 inhibito...
ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough
This content is for distribution within the UK only.
This content is for distribution wit...
ACC 2018: Alirocumab reduces cardiovascular events in high-risk patients
The ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who recei...